Chronic liver disease is characterized by three stages: chronic liver inflammation (NAFLD/NASH), liver fibrosis (cirrhosis) and eventually progressive loss of functional liver architecture and liver cancer (HCC). Early non-invasive diagnosis is necessary to halt progression and ultimately revert liver disease and concomitantly would also increase the proportion of hepatocellular carcinomas that are detected in an early stage. Halting disease progression can be mediated by changing diet and lifestyle supplemented with pharmacological intervention. The primary aim of the liver consortium is to provide a solution to liver disease-associated diagnostic challenges: 

• The consortium has focused on validating their previously-developed glycomics-based biomarker (GlycoFlameTest and GlycoHCCRisk test). For this, the consortium has access to a large set of retrospective samples from the different partner institutions. Additionally, prospective samples were collected that fulfil higher quality standards and allow multi-omics prospection for novel biomarker detection.
• A unique set of high quality standard operating procedures (SOPs) for sample collection that are compatible with all the downstream omics analyses has been established for all procedures.
• Data processing and analysis is finished or ongoing.